Hayley Virgil

Articles

Determining How to Incorporate MRD Into Care Decisions for Myeloma

January 22nd 2021

Kathleen A. Dorritie, MD, details the utility of minimal residual disease in multiple trials in the multiple myeloma space.

Atezolizumab/Bevacizumab Becomes Gold Standard in Advanced HCC, Under Exploration in Adjuvant Setting

January 22nd 2021

Because the combination of atezolizumab and bevacizumab has demonstrated superiority over sorafenib, it has become the gold standard in the frontline treatment of patients with unresectable hepatocellular carcinoma.

Mean Daily Step Count While Receiving SM-88 Correlates With Patient-Reported QoL in Metastatic Pancreatic Cancer

January 16th 2021

January 16, 2021 - Mean daily step count during the first 2 weeks of treatment with SM-88 was found to correlate with overall self-reported quality of life in patients with metastatic pancreatic cancer.

Liposomal Irinotecan Plus 5-FU Shows Real-World OS Benefit in Metastatic PDAC

January 15th 2021

January 15, 2021 - One-year overall survival was found increased the longer that patients with metastatic pancreatic ductal adenocarcinoma remained on treatment with liposomal irinotecan plus 5-fluorouracil/leucovorin.

Contribution of HIPEC to Cytoreductive Surgery in CRC Peritoneal Carcinomatosis Warrants Further Investigation

January 13th 2021

Prakash Pandalai, MD, highlighted the survival benefit of cytoreductive surgery in colorectal cancer peritoneal carcinomatosis and how it has been well documented.

BET Inhibitor CC-90010 Shows Activity in Advanced Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma

January 7th 2021

January 7, 2021 - The reversible BET inhibitor CC-90010 was found to have preliminary antitumor activity in patients with heavily pretreated, advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma.

Less Tumor Texture Variability From Baseline May Be Linked With Better Outcomes in PDAC

January 7th 2021

January 7, 2021 - Patients with pancreatic ductal adenocarcinoma who were treated with a 920 mg dose of SM-88 were less likely to experience a change in tumor texture and were found to have more favorable outcomes, according to results from a phase 2 dose-escalation trial.

Vemurafenib Plus Cetuximab/Irinotecan Improves PFS in BRAF-Mutant Metastatic CRC

January 6th 2021

January 6th, 2021 - The addition of vemurafenib to irinotecan and cetuximab led to a significant improvement in progression-free survival versus irinotecan and cetuximab alone in patients with BRAF V600E–mutated metastatic colorectal cancer.

Manochakian Breaks Down Barriers to Genetic Testing in Lung Cancer

January 4th 2021

Rami Manochakian, MD emphasized that all patients with advanced lung cancer should undergo genetic testing, both in the tissue and in the blood, to identify targetable mutations.

Practice-Changing Trials Pave the Way for Novel Approaches in Metastatic Prostate Cancer

December 31st 2020

Joseph Kim, MD, discusses pivotal trials in metastatic prostate cancer, the rise of PARP inhibitors and novel combinations under investigation, and the promise of relugolix.

x